GlassScriptPhysician profile
John K Mukai
NPI 1033159249
$2,059.42
in general payments reported to CMS, 2019-2025
22 companies · $411 in 2025
The $411 reported for 2025 was more than what 77% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $64.49 · 2022: $528 · 2023: $256 · 2024: $432 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $246.46 | 2022-2023 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $232.65 | 2024-2025 | Enhertu, Tagrisso, Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $222.01 | 2019-2025 | |
| Eisai INC. | $193.47 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $181.84 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Seagen INC. | $167.00 | 2020-2023 | Padcev |
| Glaxosmithkline, LLC. | $156.88 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $113.61 | 2019-2023 | Opdivo |
| Incyte Corporation | $73.24 | 2019-2023 | Jakafi |
| Mirati Therapeutics, INC. | $69.84 | 2024 | Krazati |
| Sobi, INC | $57.94 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $54.37 | 2025 | Xpovio |
| Gilead Sciences, INC. | $52.71 | 2022-2023 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $49.96 | 2019-2022 | |
| Blue Earth Diagnostics | $32.96 | 2025 | Posluma |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $32.66 | 2025 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $24.98 | 2019 | |
| Servier Pharmaceuticals LLC | $24.98 | 2025 | |
| Celgene Corporation | $22.82 | 2019 | |
| Lilly USA, LLC | $17.07 | 2019 | |
| Siemens Medical Solutions USA, INC. | $16.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mukai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.